UPenn Researchers Find Low Uptake of Janssen's Balversa in E

While low FGFR biomarker testing rates may be contributing to the drug's slow adoption, the analysis found low uptake even among patients who did get tested.

Related Keywords

Vivek Nimgaonkar , Janssen Balversa , Qiagen Therascreen , Ronac Mamtani , Penn Center , Genentech , Ohio State University Comprehensive Cancer Center James , Tumor Material Laboratory , Drug Administration , University Of Pennsylvania , Flatiron Health , Precision Medicine , Erica Carpenter , Circulating Tumor Material Laboratory ,